152 related articles for article (PubMed ID: 10210763)
1. [Fotemustine (Muphoran) in 22 patients with relapses of high-grade cerebral gliomas].
Malhaire JP; Lucas B; Simon H; Person H; Dam-Hieu P; Labat JP
Bull Cancer; 1999 Mar; 86(3):289-94. PubMed ID: 10210763
[TBL] [Abstract][Full Text] [Related]
2. Fotemustine in the treatment of brain primary tumors and metastases.
Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
[TBL] [Abstract][Full Text] [Related]
3. Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study.
Beauchesne PD; Taillandier L; Bernier V; Carnin C
Cancer Chemother Pharmacol; 2009 Jun; 64(1):171-5. PubMed ID: 19352662
[TBL] [Abstract][Full Text] [Related]
4. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
5. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience.
Scoccianti S; Detti B; Sardaro A; Iannalfi A; Meattini I; Leonulli BG; Borghesi S; Martinelli F; Bordi L; Ammannati F; Biti G
Anticancer Drugs; 2008 Jul; 19(6):613-20. PubMed ID: 18525321
[TBL] [Abstract][Full Text] [Related]
6. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
7. [Chemotherapy of malignant inoperable gliomas. The association of fotemustine-cisplatine-etoposide as neoadjuvants].
Frenay M; Lebrun C; Lonjon M; Marcy PY; Paquis P
Rev Neurol (Paris); 2000 Jan; 156(1):53-8. PubMed ID: 10693259
[TBL] [Abstract][Full Text] [Related]
8. [Fotemustine: a pilot phase II trial in sarcoma of the soft tissues].
Spielmann M; Berille J; Khayat D; Bizzari JP; Jacquillat C; Tursz T
Bull Cancer; 1991; 78(5):453-6. PubMed ID: 1878607
[TBL] [Abstract][Full Text] [Related]
9. Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug.
Addeo R; De Santi MS; Del Prete S; Caraglia M
Cancer Chemother Pharmacol; 2009 Oct; 64(5):863-6. PubMed ID: 19639315
[No Abstract] [Full Text] [Related]
10. Combination chemotherapy using carboplatin (JM-8) and etoposide (JET therapy) for recurrent malignant gliomas: a phase II study.
Watanabe K; Kanaya H; Fujiyama Y; Kim P
Acta Neurochir (Wien); 2002 Dec; 144(12):1265-70; discussion 1270. PubMed ID: 12478337
[TBL] [Abstract][Full Text] [Related]
11. GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status.
Pérez-Segura P; Manneh R; Ceballos I; García A; Benavides M; Fuster J; Vaz MA; Cano JM; Berros JP; Covela M; Moreno V; Quintanar T; García Bueno JM; Fernández I; Sepúlveda J
Clin Transl Oncol; 2016 Aug; 18(8):805-12. PubMed ID: 26542177
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of fotemustine in pediatric patients with refractory brain tumors.
Hargrave DR; Bouffet E; Gammon J; Tariq N; Grant RM; Baruchel S
Cancer; 2002 Sep; 95(6):1294-301. PubMed ID: 12216098
[TBL] [Abstract][Full Text] [Related]
13. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas.
Levin VA; Hess KR; Choucair A; Flynn PJ; Jaeckle KA; Kyritsis AP; Yung WK; Prados MD; Bruner JM; Ictech S; Gleason MJ; Kim HW
Clin Cancer Res; 2003 Mar; 9(3):981-90. PubMed ID: 12631596
[TBL] [Abstract][Full Text] [Related]
14. A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma.
Fabrini MG; Silvano G; Lolli I; Perrone F; Marsella A; Scotti V; Cionini L
J Neurooncol; 2009 Mar; 92(1):79-86. PubMed ID: 19018476
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy.
Mizoe JE; Tsujii H; Hasegawa A; Yanagi T; Takagi R; Kamada T; Tsuji H; Takakura K;
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):390-6. PubMed ID: 17459607
[TBL] [Abstract][Full Text] [Related]
16. BCNU-DBD (Dibromodulcitol) chemotherapy of recurrent supratentorial anaplastic astrocytomas and glioblastomas.
Vitanovics D; Sipos L; Afra D
Neoplasma; 2002; 49(5):342-5. PubMed ID: 12458335
[TBL] [Abstract][Full Text] [Related]
17. Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study.
Addeo R; Lamberti G; Simonetti G; Iodice P; Marinelli A; Montella L; Cappabianca S; Gaviani P; Caraglia M; Prete SD; Silvani A
CNS Oncol; 2019 Jun; 8(2):CNS32. PubMed ID: 31290692
[No Abstract] [Full Text] [Related]
18. Low-dose fotemustine as second-line chemotherapy for recurrent glioblastoma multiforme.
De Felice F; Bulzonetti N; Musio D; D'Elia A; Salvati M; Tombolini V
Anticancer Res; 2013 Sep; 33(9):4013-6. PubMed ID: 24023343
[TBL] [Abstract][Full Text] [Related]
19. Recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2) immunotherapy with ranimustine chemotherapy and concurrent radiation therapy for malignant astrocytomas.
Fukushima T; Yamamoto M; Oshiro S; Tsugu H; Hirakawa K; Soma G
Anticancer Res; 2003; 23(6a):4473-81. PubMed ID: 14666736
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma.
Santoni M; Scoccianti S; Lolli I; Fabrini MG; Silvano G; Detti B; Perrone F; Savio G; Iacovelli R; Burattini L; Berardi R; Cascinu S
J Neurooncol; 2013 Jul; 113(3):397-401. PubMed ID: 23564276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]